A5102972919- BRCA gene mutations in cancer
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Ovarian cancer diagnosis and treatment
- Nutrition, Genetics, and Disease
- PARP inhibition in cancer therapy
- Breast Lesions and Carcinomas
- Genetic factors in colorectal cancer
- DNA Repair Mechanisms
- HER2/EGFR in Cancer Research
- Family Support in Illness
- Cancer Immunotherapy and Biomarkers
- Health Systems, Economic Evaluations, Quality of Life
- Childhood Cancer Survivors' Quality of Life
- Cancer Risks and Factors
- Global Cancer Incidence and Screening
- Health and Medical Studies
- Breast Implant and Reconstruction
- Patient-Provider Communication in Healthcare
- Bone Metabolism and Diseases
- Endometrial and Cervical Cancer Treatments
- Economic and Financial Impacts of Cancer
- Cancer-related Molecular Pathways
University Hospital Cologne
2016-2025
University of Cologne
2016-2025
Centrum für Integrierte Onkologie
2015-2024
Johannes Gutenberg University Mainz
2023
Klinik für Frauenheilkunde
2009-2020
Integrated Oncology (United States)
2019-2020
University Hospital Heidelberg
2011-2019
Heidelberg University
2007-2019
Charité - Universitätsmedizin Berlin
2014-2019
Sana Klinikum
2018-2019
BackgroundIn the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data potential prognostic predictive role of homologous recombination deficiency (HRD).Patients methodsPatients were randomized paclitaxel plus nonpegylated liposomal doxorubicin (Myocet®) (PM) or PM (PMCb). The secondary study end points...
506 Background: The GeparNuevo trial investigated the addition of durvalumab, an anti-PD-L1 checkpoint inhibitor (CPI), to standard neoadjuvant chemotherapy (NACT) in patients with early TNBC. Durvalumab increased pathological complete response (pCR) rate particularly treated durvalumab alone before start (Loibl et al. Ann Oncol 2019). Methods: randomized cT1b-cT4a-d tumors and centrally confirmed TNBC (D) 1.5 g i.v. or placebo every 4 weeks. D/placebo monotherapy (0.75 i.v.) was given for...
The GeparSepto trial demonstrated that weekly nanoparticle albumin-bound (NAB)-paclitaxel significantly improves the pathologic complete remission rate compared with solvent-based (sb) paclitaxel followed by epirubicin plus cyclophosphamide as neoadjuvant treatment in patients primary breast cancer (BC). Here, we report data on long-term outcomes.Patients histologically confirmed BC were randomly assigned a 1:1 ratio to 12 times NAB-paclitaxel 150 mg/m2 (after study amendment, 125 mg/m2) or...
There is no international consensus up to which age women with a diagnosis of triple-negative breast cancer (TNBC) and family history or ovarian should be offered genetic testing for germline BRCA1 BRCA2 (gBRCA) mutations. Here, we explored the association at TNBC prevalence pathogenic gBRCA mutations in this patient group. The study comprised 802 (median 40 years, range 19–76) oestrogen receptor, progesterone human epidermal growth factor receptor type 2 negative cancers, who had relatives...
Abstract This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 pCR from five neoadjuvant GBG/AGO-B trials fulfill the inclusion criteria of this analysis. Primary endpoint is disease-free survival (DFS); secondary endpoints distant DFS (DDFS) and overall (OS). After median follow-up 57.6 months, significantly worse for positive lymph nodes (cN+ vs cN0 hazard ratio [HR] 1.94, 95%CI...
<b><i>Introduction:</i></b> Each year the interdisciplinary AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Breast Committee on Diagnosis and Treatment of Cancer provides updated state-of-the-art recommendations for early metastatic breast cancer. <b><i>Methods:</i></b> The evidence-based treatment cancer have been released in March 2024. <b><i>Results Conclusion:</i></b> This...
104 Background: Combining immune-checkpoint inhibitors with chemotherapy yielded high response rates in patients (pts) metastatic TNBC. Therefore, we evaluated the addition of durvalumab, an anti-PD-L1 checkpoint inhibitor, to standard neoadjuvant pts primary Methods: GeparNuevo randomized durvalumab (D) 1.5 g i.v. or placebo every 4 weeks (wks). D/placebo monotherapy (0.75 i.v.) was given for first 2 wks (window phase), followed by a biopsy and plus nab-paclitaxel (nP) 125 mg/m² weekly 12...
The chemotherapy backbone for patients with high-grade advanced epithelial ovarian cancer (HG-AOC) is carboplatin and paclitaxel followed by a maintenance therapy either bevacizumab, PARP inhibitor, or combination of both, which defined the presence homologous recombination deficiency (HRD) BRCA1/2 status. This study included primary diagnosis HG-AOC treated between December 2019 2021. HRD status was measured using Myriad myChoice® test on all an indication tumor testing. Germline testing...
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents 2024 update evidence-based recommendations for diagnosis and treatment patients with locally advanced metastatic breast cancer.
Patients who actively engage in their medical decision-making processes can experience better health outcomes. This exploratory study aimed to identify predictors of preferred and actual roles healthy women with BRCA1/2 pathogenic variants (PVs). Women PVs without a history breast and/or ovarian cancer were recruited six centres across Germany. Those returning the baseline questionnaires (T1) randomly assigned intervention or control group (IG, CG). The IG completed decision-coaching (DC)...
Abstract Backgound: The GeparOLA study evaluated paclitaxel(P) plus olaparib(O) in neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer (eBC) homologous recombination deficiency (HRD). HRD was defined by high HRD-score or germline(g)/tumor(t) BRCA1/2 mutations (g/tBRCA1/2mut). Here, we report long-term outcome data. Patients and Methods: (NCT02789332) a randomized, multicenter, prospective, open-label, phase II trial. eBC, HRD, indication (cT2-cT4a-d cT1c cN+...
Background: The treatment of Hodgkin's disease (HD; also called lymphoma) in children and adolescents with radiotherapy chemotherapy leads to high survival rates but has a number late effects.The most serious one is the development secondary malignant tumor, usually field that was irradiated.In women, breast cancer can arise this way.Methods: Data on occurrence (sBC) were collected from 590 women who treated five consecutive pediatric HD studies years 1978-1995 then re-evaluated follow-up...
The conversion of initially histologically confirmed axillary lymph node-positive (pN+) to ypN0 after neoadjuvant systemic treatment (NAST) is an important prognostic factor in breast cancer (BC) patients and may influence surgical de-escalation strategies. We aimed determine pCR rates nodes (pCR-LN), the (pCR-B), both (tpCR) women who present with pN+ BC, assess predictors for response impact pCR-LN, pCR-B, tpCR on invasive disease-free survival (iDFS).Retrospective, exploratory analysis...